Author: ICWA

Stealth Adapted Viruses

Stealth Adapted Viruses

Dr. John Martin is the original whistleblower on ‘stealth viral contamination’ of vaccinations. His tenure spanned 70’s, 80’s, and 90’s during which time he held many prominent positions including the FDA, Virology Department and the National Cancer Institute, Biological Resources Branch.

In his own words:

“What makes vaccines so troublesome is that their production and administration allows viral contamination to breach the two natural barriers that often restrict cross-species infections:

First is the skin. Direct inoculation of vaccines breaches this natural barrier and has been shown to produce increased infections in animals and humans. Such was the case when SV40 was injected intramuscularly in contaminated Salk polio vaccine. Later it was learned that Sabin’s orally administered polio vaccines were safer since the live simian viruses were digested in the stomach and thereby inactivated. Additionally risky, when it comes to breaking the skin barrier, is the chance of transmitting viruses from one person to another through the use of unsterilized needles.

Second is the unique and natural viral surface characteristics that reduce the chance that viruses might jump species. The mixing of vaccine viruses with others found in the cells and tissues used to develop the vaccine can potentially lead to the development of new recombinant mutants that are more adaptive and have wider host range than either of the original viruses. This can especially happen when a live viral vaccine produced in cells from one species is then given to another species.

Also of concern is the transmission of new genetic information along with the vaccine virus. For instance, early adenoviral vaccines, produced in rhesus monkeys’ kidney cells, developed to protect people against respiratory infections, incorporated parts ofthe SV40 virus that remained as a vaccine contaminant even after production of the vaccine virus was switched to human cells. Numerous other vaccines, especially those that were used in early field trials in Africa, should be analyzed for those genetic components which characterize today’s monkey and human pathogens.

Unfortunately, this new awareness of potential problems with live viral vaccines has had little impact on the viral vaccine approval process. Seemingly, U.S. government agencies, principally the FDA, have been reluctant to impose additional testing requirements on vaccines once they are approved for use. In effect, government officials are given a single opportunity to decide on a new vaccine’s safety. Even then, government regulators themselves may be denied certain critical information belonging to the vaccine industry. Specifically, FDA regulations are written so as not to compel industry to reveal testing information not directly pertaining to the lots submitted for clinical use. The FDA is reluctant to admit its lack of knowledge about vaccines to the medical/scientific community. Yet, practicing physicians are expected to unquestionably endorse the safety of vaccines under all circumstances and to all individuals.”

He rang the alarm bell all those years ago and the FDA is only just now beginning the discussion of “stealth viruses in cell lines”….

FDA says:

“Some of these tumor-forming cell lines may contain cancer-causing viruses that are not actively reproducing. Such viruses are hard to detect using standard methods. These latent, or “quiet,” viruses pose a potential threat, since they might become active under vaccine manufacturing conditions. Therefore, to ensure the safety of vaccines, our laboratory is investigating ways to activate latent viruses in cell lines and to detect the activated viruses, as well as other unknown viruses, using new technologies.”

You can read more here:

To learn more about the impact of vaccination on the human genome — and on your genes, attend our upcoming (MARCH 3, 2018) Future of Immunity Lecture: Genes and Vaccines at the University of Washington, Bothell. Details can be found HERE.

Are vaccine aluminum adjuvants safe?

Are vaccine aluminum adjuvants safe?

Dr. Jose G. Dores, a professor at the University of Brasilia’s Department of Nutritional Sciences who recently published a study in the International Journal of Environmental Research and Public Health, offers the following observation:

“Despite their long use as active agents of medicines and fungicides, the safety levels of these substances have never been determined, either for animals or for adult humans, much less for fetuses, newborns, infants, and children.”


And a team of researchers, published in the Journal of Inorganic Chemistry in December of 2017:

“Critical analysis of reference studies on the toxicokinetics of aluminum-based adjuvants”

“We reviewed the three toxicokinetic reference studies commonly used to suggest that aluminum (Al)-based adjuvants are innocuous. A single experimental study was carried out using isotopic 26Al (Flarend et al., Vaccine, 1997). This study used aluminum salts resembling those used in vaccines but ignored adjuvant uptake by cells that was not fully documented at the time. It was conducted over a short period of time (28 days) and used only two rabbits per adjuvant. At the endpoint, Al elimination in the urine accounted for 6% for Al hydroxide and 22% for Al phosphate, both results being incompatible with rapid elimination of vaccine-derived Al in urine. Two theoretical studies have evaluated the potential risk of vaccine Al in infants, by reference to an oral “minimal risk level” (MRL) extrapolated from animal studies. Keith et al. (Vaccine, 2002) used a high MRL (2 mg/kg/d), an erroneous model of 100% immediate absorption of vaccine Al, and did not consider renal and blood-brain barrier immaturity. Mitkus et al. (Vaccine, 2011) only considered solubilized Al, with erroneous calculations of absorption duration. Systemic Al particle diffusion and neuro-inflammatory potential were omitted. The MRL they used was both inappropriate (oral Al vs. injected adjuvant) and still too high (1 mg/kg/d) regarding recent animal studies. Both paucity and serious weaknesses of reference studies strongly suggest that novel experimental studies of Al adjuvants toxicokinetics should be performed on the long-term, including both neonatal and adult exposures, to ensure their safety and restore population confidence in Al-containing vaccines.”


2018 Lecture Series

2018 Lecture Series

2018 Future of Immunity Lecture Series

The American Academy of Pediatrics acknowledges that parents who delay or refuse vaccines tend to be highly educated and knowledgeable about vaccines.

What do they know?

Part One in the Lecture Series:

Community Immunity? Does your vaccination protect anyone else?

When: Saturday, January 20, 2018 from 1:30-4:30
Where: Discovery Hall 061 at the University of Washington, Bothell campus*
Cost: Free (but if your budget allows, $10 suggested donation at the door would be much appreciated to help cover our costs.)
Parking: On campus ($4)

Kids Allowed? Yes! We understand the challenges of parenting, and trying to sneak away. Kids are welcome, but it will likely be dull for them, so please bring quiet, diverting toys.

Featured Speakers:

Tetyana Obukhanych, Ph.D. Founding Director of Physicians for Informed Consent, and Founding Member of Building Bridges in Children’s Health

Dr. Obukhanych earned a PhD in Immunology at The Rockefeller University, New York, NY and has held postdoctoral appointments in prominent immunology laboratories affiliated with Harvard Medical School and Stanford University School of Medicine. She is a Founding Director of Physicians for Informed Consent, a non-profit organization of doctors and scientists dedicated to safeguarding informed consent in vaccination. She is the author of Vaccine Illusion, and she lectures frequently at conferences and educational events throughout North America, as well as at Building Bridges in Children’s Health (BBCH), an online community that equips parents with the knowledge of up-to-date science relevant to children’s health in order to empower them in their own communications with medical doctors. 

Mary Holland, J.D. Research Scholar and Director of the Graduate Lawyering Program at NYU School of Law

Mary Holland is a legal expert on informed consent and has testified on vaccine matters at the United Nations and in New York, California, Maine, West Virginia and Vermont legislatures. She has written often-cited law review papers, articles on vaccine law and policy, and is the co-author and co-editor of the book Vaccine Epidemic and an upcoming book about HPV vaccines. She has lectured widely and has appeared in several documentaries and on various television and radio broadcasts.


*UWB is a rented venue and not affiliated with this event. This is an Informed Choice WA event.


Neil Z. Miller, medical research journalist: Where is the alarm?

Neil Z. Miller, medical research journalist: Where is the alarm?